TKI Selection in CML Demands Nuanced Approaches : vimarsana.

Choosing the most effective TKIs for individual patients with chronic myeloid leukemia requires decision making based on efficacy data, agent safety profiles, and patient characteristics, according to Michael Deininger, MD.

Related Keywords

Houston , Texas , United States , Michael Deininger , Society Of Hematologic Oncology , Meeting Of The Society Hematologic Oncology , Novartis , Versiti Blood Research Institute , Bristol Myers Squibb , Pfizer , Annual Society , Hematologic Oncology , Rational Choice , Annual Meeting , Society Hematologic Oncology , Kinase Inhibitor Trial , Chronic Myeloid Leukemia , Year Update , Optic Trial , Dose Optimization Study , Patients With Chronic Myeloid Leukemia , D ,